The Spike Protein and Hypothyroidism: From Long COVID to the Induction of Cancer A new study supports my hypothesis from 2021 that SARS-CoV-2 is a carcinogenic virus. WALTER M CHESNUT MAY 19
Four years ago, I read an autopsy report of eight COVID-19 patients (paper linked in my 2021 post). The report noted the curious finding that two of the eight had previously unknown thyroid cancer. Given that my research at the time had already led me to believe the virus was carcinogenic, this discovery further bolstered my resolve that I was on the right track. Thyroid cancer is rare. It accounts for less than 1% of cancer diagnoses in the US each year.
Thyroid cancer is relatively uncommon compared to other cancers. In the United States, it is estimated that in 2021 approximately 44,000 people will receive a new diagnosis of thyroid cancer, compared to over 280,000 with breast cancer and over 150,000 with colon cancer.
As I stated in my post of 2021, the odds of 25% of any population having thyroid cancer, especially undiagnosed, would be statistically almost impossible. I hypothesized that either direct infection by SARS-CoV-2, its reactivation of EBV (another risk factor for thyroid cancer) or both were most likely a factor.
I believe both instances are due to SARS-CoV-2 infection. One due to direct thyroid infection and the other due to an active infection of or reactivation of EBV. EBV is considered a significant cause of papillary thyroid cancer. Perhaps both factors are in play as EBV could have been active in both patients and the body may have cleared the virus in the other.
A study from Wuhan University published 25 May found that EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.
At the time, I did not directly implicate the Spike Protein as I did not have sufficient evidence. However, a study has just been published that supports the claim that the Spike Protein is itself responsible. The Spike Protein, via COVID vaccination, causes an increased risk of hypothyroidism.
Results
The risk of subacute thyroiditis remained unchanged (95% CIs included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months postvaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99; 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months postvaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13).
Conclusion
COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.
Hypothyroidism is associated with a significantly higher incidence of cancer IN THOSE UNDER 60, as a 2023 study found.
Results
Of a total population of 506,749 patients, 23,570 (4.7%) were diagnosed with hypothyroidism. Patients with this diagnosis had a significantly higher frequency of cancer than that found in non-hypothyroid subjects (OR 2.09, 95% confidence interval [CI] 2.01−2.17). This higher frequency was found both in women (OR 1.99, 95% CI 1.90−2.08) and in men (OR 2.83, 95% CI 2.63−3.05). However, this higher frequency of cancer was not observed in hypothyroid patients older than 60 years (OR 0.97, 95% CI 0.92−1.02). Although the frequency of most of the neoplasms studied individually was higher in the population with hypothyroidism, we observed that hypothyroid patients over 60 years of age had a significant decrease in the frequency of prostate, lung, colorectal, and liver cancer.
Conclusion
Data from this hospital cohort suggest that there is a significant association between the diagnosis of hypothyroidism and cancer. However, this association is less evident in hypothyroid patients older than 60 years.
Beyond the potential risk for developing cancer, hypothyroidism may play an important role in Long COVID, as the similarities between the two are remarkable.
Conversely, a case-control study focusing on anosmia due to SARS-CoV-2 found a significant correlation between hypothyroidism and the prolongation of smell dysfunction in COVID-19 patients. It was postulated that this continuation of anosmia is due to direct virus-induced injury to the thyroid and olfactory nerve. Thyroid hormones regulate development of nearly all systems in the body, including the neural maturation of olfactory receptor neurons. Therefore, impaired thyroid hormone secretion or action due to SARS-CoV-2 could affect the development of these neurons, ultimately leading to COVID-19-induced anosmia (56). There are few studies focusing on potential thyroid dysfunctions during long COVID, highlighting the need for further research to understand the incidence and complications of long COVID and how the thyroid gland is related to this condition.
I am not making the assertion that if one develops hypothyroidism post infection or vaccination that deleterious outcomes to one’s health are inevitable. What I would like us to consider is the totality of deleterious effects the Spike Protein can have on our bodies, and how we must listen to and monitor our bodies. This is so that we can take immediate action in addressing any injury or pathology that the virus and/or its proteins may induce.
Stop the Spike. Mitigate its damage. I will continue searching for ways to accomplish both.
Thank you, as always, for your dialogue, readership and support. I am especially grateful this morning as over the weekend we gained a new Founding Member. Please have a blessed and hopeful week. 穗蛋白和甲状腺功能减退症：从长康德到癌症的诱导新的研究支持我的假设来自2021年，即SARS-COV-2是一种致癌病毒。 沃尔特M Chesnut 5月19日在4年前阅读了APP中，我读了八个Covid-19患者的尸检报告（在我的2021篇文章中挂钩）。 报告指出，八个中有两个先前未知的甲状腺癌。 鉴于当时的研究已经让我相信病毒是致癌的，这一发现进一步加强了我在正确的轨道上的决心。 甲状腺癌是罕见的。 它每年占美国癌症诊断的1％。 与其他癌症相比，甲状腺癌相对罕见。 在美国，据估计，在2021年，大约44,000人将获得甲状腺癌的新诊断，而乳腺癌超过280,000克，并且结肠癌超过150,000。 甲状腺癌（乳头状和卵泡）https://www.thyroid.org/thyroid-cancer/%E6%AD%A3%E5%A6%82%E6%88%91%E5%9C%A82021%E5%B9%B4%E7%9A%84%E5%B8%96%E5%AD%90%E4%B8%AD%E6%89%80%E8%BF%B0%EF%BC%8C%E5%8D%A0%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C%E7%9A%84%E4%BB%BB%E4%BD%95%E4%BA%BA%E5%8F%A3%E7%9A%84%E5%8F%AF%E8%83%BD%E6%80%A7%EF%BC%8C%E7%89%B9%E5%88%AB%E6%98%AF%E6%9C%AA%E6%8F%AD%E8%A7%86 我假设SARS-COV-2直接感染，它的EBV再激活（甲状腺癌的另一个危险因素）或两者最有可能是一个因素。 我相信两个实例都是由于SARS-COV-2感染。 一个原因是直接甲状腺感染，另一个由于EBV的活跃感染或再活化。 EBV被认为是乳头状甲状腺癌的重要原因。 也许这两个因素都在发挥eBV，因为EBV可能在两个患者中活跃，身体可能已经清除了其他病毒。 武汉大学出版的研究25日可能发现EBV / SARS-COV-2辛融合与发热和炎症增加有关。 EBV Reactivation可以与Covid-19的严重程度相关联。 以前未知的甲状腺癌HTTPS://WMCResearch.org/Preveary-unknown-thyroid-Cancer/当时我没有直接暗示穗蛋白，因为我没有足够的证据。 然而，刚刚发表了一项研究，支持尖刺蛋白本身负责的索赔。 通过Covid疫苗接种刺激蛋白质导致甲状腺功能亢进的风险增加。 结果亚急性甲状腺炎的风险保持不变（95％CIS包括1）。 从3至9个月内观察到甲状腺功能亢进风险的显着降低（危险比[HRS]：0.65-0.89，所有95％CIS以下1），但这种趋势在12个月内并不重要（HR：0.99; 95 相比之下，甲状腺功能减退症的风险显着增加到5至12个月（HR：1.14-1.30，所有95％CIS以上1）。 在mRNA疫苗受者中，甲状腺功能亢进症和甲状腺功能减退症的风险在12个月内显着升高（HR：1.16-2.13）。 结论Covid-19疫苗接种与甲状腺功能亢进的风险降低，甲状腺功能亢进的风险增加，突出了持续甲状腺功能监测的需求。 Covid-19疫苗接种后的长期甲状腺结果：Trinetx网络的233 496名患者的队列研究HTTPS://academer.oup.com/jcem / advance-article-abstract/doi/10 总人口506,749名患者，23,570（4.7％）被诊断出甲状腺功能亢进。 患有这种诊断的患者患有明显较高的癌症频率明显高于非甲状腺细胞受试者（或2.09,95％置信区间[CI] 2.01-2.17）。 在女性（或1.99,95％CI 1.90-2.08）和男性（或2.83,95％CI 2.63-3.05）中发现这种较高频率。 然而，在60岁的甲状腺功能率患者（或0.97,95％CI 0.92-1.02）中未观察到这种较高癌症的癌症较高的癌症。 虽然具有甲状腺功能减退症的人群中大多数肿瘤的频率在人口中单独研究，但我们观察到60岁以上的甲状腺功能亢进患者在前列腺，肺，结肠直肠癌和肝癌的频率下显着降低。 结论来自该医院队列的数据表明，甲状腺功能亢进和癌症的诊断之间存在重大关联。 然而，这种关联在60岁的甲状腺功能率患者中不太明显。 甲状腺功能减退症患者癌症的患病率：使用大数据工具分析：//www.elsevier.es/en-revista- endicrocologia-dabetes-nutricion-english -413-articulo 甲状腺功能亢进对体内的影响。 https：//www.healthline.com/health/hypothyroidism/effects--七滴虫功能有证据。 相反，对SARS-COV-2引起的案例对照研究侧重于ANOSMIA，发现甲状腺功能减退症与Covid-19患者中的嗅觉功能障碍之间的显着相关性。 假设这种延续的Anosmia是由于病毒诱导的甲状腺和嗅到神经损伤。 甲状腺激素调节身体中几乎所有系统的发育，包括嗅觉受体神经元的神经成熟。 因此，由于SARS-COV-2引起的甲状腺激素分泌或动作受损可能影响这些神经元的发育，最终导致Covid-19诱导的Anosmia（56）。 很少有关于长Covid期间潜在的甲状腺功能障碍的研究，突出了进一步研究的需要，以了解长Covid的发病率和并发症以及甲状腺与这种情况有关的情况。 Covid-19期间的甲状腺功能和成人后的后Covid并发症：系统性评论https://www.frontiersin.org/journals/encocrinologic/articles/10.3389/fendo.2024.14 我希望我们考虑的是有害影响的全体尖刺蛋白可以在我们的身体上，以及我们必须如何倾听和监控我们的身体。 这是为了解决病毒和/或其蛋白质可能诱导的任何伤害或病理来立即采取行动。 停止钉子。 减轻它的伤害。 我将继续搜索两者的方法。 衷心感谢您的对话，读者和支持。 我今天早上特别感激，截至周末，我们获得了一个新的创始成员。 请有一个幸福和希望的一周。
The Spike Protein and Hypothyroidism: From Long COVID to the Induction of Cancer
A new study supports my hypothesis from 2021 that SARS-CoV-2 is a carcinogenic virus.
WALTER M CHESNUT
MAY 19
尖峰蛋白和甲状腺功能减退症：从长期到癌症的诱导
一项新的研究支持我从2021年开始的假设，即SARS-COV-2是一种致癌病毒
https://open.substack.com/pub/wmcresearch/p/the-spike-protein-and-hypothyroidism
READ IN APP
Four years ago, I read an autopsy report of eight COVID-19 patients (paper linked in my 2021 post). The report noted the curious finding that two of the eight had previously unknown thyroid cancer. Given that my research at the time had already led me to believe the virus was carcinogenic, this discovery further bolstered my resolve that I was on the right track. Thyroid cancer is rare. It accounts for less than 1% of cancer diagnoses in the US each year.
Thyroid cancer is relatively uncommon compared to other cancers. In the United States, it is estimated that in 2021 approximately 44,000 people will receive a new diagnosis of thyroid cancer, compared to over 280,000 with breast cancer and over 150,000 with colon cancer.
Thyroid Cancer (Papillary and Follicular)
https://www.thyroid.org/thyroid-cancer/
As I stated in my post of 2021, the odds of 25% of any population having thyroid cancer, especially undiagnosed, would be statistically almost impossible. I hypothesized that either direct infection by SARS-CoV-2, its reactivation of EBV (another risk factor for thyroid cancer) or both were most likely a factor.
I believe both instances are due to SARS-CoV-2 infection. One due to direct thyroid infection and the other due to an active infection of or reactivation of EBV. EBV is considered a significant cause of papillary thyroid cancer. Perhaps both factors are in play as EBV could have been active in both patients and the body may have cleared the virus in the other.
A study from Wuhan University published 25 May found that EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19.
Previously Unknown Thyroid Cancer
https://wmcresearch.org/previously-unknown-thyroid-cancer/
At the time, I did not directly implicate the Spike Protein as I did not have sufficient evidence. However, a study has just been published that supports the claim that the Spike Protein is itself responsible. The Spike Protein, via COVID vaccination, causes an increased risk of hypothyroidism.
Results
The risk of subacute thyroiditis remained unchanged (95% CIs included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months postvaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99; 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months postvaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13).
Conclusion
COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.
Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network
https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgaf064/7990879
Hypothyroidism is associated with a significantly higher incidence of cancer IN THOSE UNDER 60, as a 2023 study found.
Results
Of a total population of 506,749 patients, 23,570 (4.7%) were diagnosed with hypothyroidism. Patients with this diagnosis had a significantly higher frequency of cancer than that found in non-hypothyroid subjects (OR 2.09, 95% confidence interval [CI] 2.01−2.17). This higher frequency was found both in women (OR 1.99, 95% CI 1.90−2.08) and in men (OR 2.83, 95% CI 2.63−3.05). However, this higher frequency of cancer was not observed in hypothyroid patients older than 60 years (OR 0.97, 95% CI 0.92−1.02). Although the frequency of most of the neoplasms studied individually was higher in the population with hypothyroidism, we observed that hypothyroid patients over 60 years of age had a significant decrease in the frequency of prostate, lung, colorectal, and liver cancer.
Conclusion
Data from this hospital cohort suggest that there is a significant association between the diagnosis of hypothyroidism and cancer. However, this association is less evident in hypothyroid patients older than 60 years.
Prevalence of cancer in patients with hypothyroidism: Analysis using big data tools
https://www.elsevier.es/en-revista-endocrinologia-diabetes-nutricion-english-ed--413-articulo-prevalence-cancer-in-patients-with-S2530018023001233
Beyond the potential risk for developing cancer, hypothyroidism may play an important role in Long COVID, as the similarities between the two are remarkable.
The effects of hypothyroidism on the body.
https://www.healthline.com/health/hypothyroidism/effects-of-hypothyroidism
There is evidence for this.
Conversely, a case-control study focusing on anosmia due to SARS-CoV-2 found a significant correlation between hypothyroidism and the prolongation of smell dysfunction in COVID-19 patients. It was postulated that this continuation of anosmia is due to direct virus-induced injury to the thyroid and olfactory nerve. Thyroid hormones regulate development of nearly all systems in the body, including the neural maturation of olfactory receptor neurons. Therefore, impaired thyroid hormone secretion or action due to SARS-CoV-2 could affect the development of these neurons, ultimately leading to COVID-19-induced anosmia (56). There are few studies focusing on potential thyroid dysfunctions during long COVID, highlighting the need for further research to understand the incidence and complications of long COVID and how the thyroid gland is related to this condition.
Thyroid function during COVID-19 and post-COVID complications in adults: a systematic review
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1477389/full
I am not making the assertion that if one develops hypothyroidism post infection or vaccination that deleterious outcomes to one’s health are inevitable. What I would like us to consider is the totality of deleterious effects the Spike Protein can have on our bodies, and how we must listen to and monitor our bodies. This is so that we can take immediate action in addressing any injury or pathology that the virus and/or its proteins may induce.
Stop the Spike. Mitigate its damage. I will continue searching for ways to accomplish both.
Thank you, as always, for your dialogue, readership and support. I am especially grateful this morning as over the weekend we gained a new Founding Member. Please have a blessed and hopeful week. 穗蛋白和甲状腺功能减退症：从长康德到癌症的诱导新的研究支持我的假设来自2021年，即SARS-COV-2是一种致癌病毒。 沃尔特M Chesnut 5月19日在4年前阅读了APP中，我读了八个Covid-19患者的尸检报告（在我的2021篇文章中挂钩）。 报告指出，八个中有两个先前未知的甲状腺癌。 鉴于当时的研究已经让我相信病毒是致癌的，这一发现进一步加强了我在正确的轨道上的决心。 甲状腺癌是罕见的。 它每年占美国癌症诊断的1％。 与其他癌症相比，甲状腺癌相对罕见。 在美国，据估计，在2021年，大约44,000人将获得甲状腺癌的新诊断，而乳腺癌超过280,000克，并且结肠癌超过150,000。 甲状腺癌（乳头状和卵泡）https://www.thyroid.org/thyroid-cancer/%E6%AD%A3%E5%A6%82%E6%88%91%E5%9C%A82021%E5%B9%B4%E7%9A%84%E5%B8%96%E5%AD%90%E4%B8%AD%E6%89%80%E8%BF%B0%EF%BC%8C%E5%8D%A0%E7%94%B2%E7%8A%B6%E8%85%BA%E7%99%8C%E7%9A%84%E4%BB%BB%E4%BD%95%E4%BA%BA%E5%8F%A3%E7%9A%84%E5%8F%AF%E8%83%BD%E6%80%A7%EF%BC%8C%E7%89%B9%E5%88%AB%E6%98%AF%E6%9C%AA%E6%8F%AD%E8%A7%86 我假设SARS-COV-2直接感染，它的EBV再激活（甲状腺癌的另一个危险因素）或两者最有可能是一个因素。 我相信两个实例都是由于SARS-COV-2感染。 一个原因是直接甲状腺感染，另一个由于EBV的活跃感染或再活化。 EBV被认为是乳头状甲状腺癌的重要原因。 也许这两个因素都在发挥eBV，因为EBV可能在两个患者中活跃，身体可能已经清除了其他病毒。 武汉大学出版的研究25日可能发现EBV / SARS-COV-2辛融合与发热和炎症增加有关。 EBV Reactivation可以与Covid-19的严重程度相关联。 以前未知的甲状腺癌HTTPS://WMCResearch.org/Preveary-unknown-thyroid-Cancer/当时我没有直接暗示穗蛋白，因为我没有足够的证据。 然而，刚刚发表了一项研究，支持尖刺蛋白本身负责的索赔。 通过Covid疫苗接种刺激蛋白质导致甲状腺功能亢进的风险增加。 结果亚急性甲状腺炎的风险保持不变（95％CIS包括1）。 从3至9个月内观察到甲状腺功能亢进风险的显着降低（危险比[HRS]：0.65-0.89，所有95％CIS以下1），但这种趋势在12个月内并不重要（HR：0.99; 95 相比之下，甲状腺功能减退症的风险显着增加到5至12个月（HR：1.14-1.30，所有95％CIS以上1）。 在mRNA疫苗受者中，甲状腺功能亢进症和甲状腺功能减退症的风险在12个月内显着升高（HR：1.16-2.13）。 结论Covid-19疫苗接种与甲状腺功能亢进的风险降低，甲状腺功能亢进的风险增加，突出了持续甲状腺功能监测的需求。 Covid-19疫苗接种后的长期甲状腺结果：Trinetx网络的233 496名患者的队列研究HTTPS://academer.oup.com/jcem / advance-article-abstract/doi/10 总人口506,749名患者，23,570（4.7％）被诊断出甲状腺功能亢进。 患有这种诊断的患者患有明显较高的癌症频率明显高于非甲状腺细胞受试者（或2.09,95％置信区间[CI] 2.01-2.17）。 在女性（或1.99,95％CI 1.90-2.08）和男性（或2.83,95％CI 2.63-3.05）中发现这种较高频率。 然而，在60岁的甲状腺功能率患者（或0.97,95％CI 0.92-1.02）中未观察到这种较高癌症的癌症较高的癌症。 虽然具有甲状腺功能减退症的人群中大多数肿瘤的频率在人口中单独研究，但我们观察到60岁以上的甲状腺功能亢进患者在前列腺，肺，结肠直肠癌和肝癌的频率下显着降低。 结论来自该医院队列的数据表明，甲状腺功能亢进和癌症的诊断之间存在重大关联。 然而，这种关联在60岁的甲状腺功能率患者中不太明显。 甲状腺功能减退症患者癌症的患病率：使用大数据工具分析：//www.elsevier.es/en-revista- endicrocologia-dabetes-nutricion-english -413-articulo 甲状腺功能亢进对体内的影响。 https：//www.healthline.com/health/hypothyroidism/effects--七滴虫功能有证据。 相反，对SARS-COV-2引起的案例对照研究侧重于ANOSMIA，发现甲状腺功能减退症与Covid-19患者中的嗅觉功能障碍之间的显着相关性。 假设这种延续的Anosmia是由于病毒诱导的甲状腺和嗅到神经损伤。 甲状腺激素调节身体中几乎所有系统的发育，包括嗅觉受体神经元的神经成熟。 因此，由于SARS-COV-2引起的甲状腺激素分泌或动作受损可能影响这些神经元的发育，最终导致Covid-19诱导的Anosmia（56）。 很少有关于长Covid期间潜在的甲状腺功能障碍的研究，突出了进一步研究的需要，以了解长Covid的发病率和并发症以及甲状腺与这种情况有关的情况。 Covid-19期间的甲状腺功能和成人后的后Covid并发症：系统性评论https://www.frontiersin.org/journals/encocrinologic/articles/10.3389/fendo.2024.14 我希望我们考虑的是有害影响的全体尖刺蛋白可以在我们的身体上，以及我们必须如何倾听和监控我们的身体。 这是为了解决病毒和/或其蛋白质可能诱导的任何伤害或病理来立即采取行动。 停止钉子。 减轻它的伤害。 我将继续搜索两者的方法。 衷心感谢您的对话，读者和支持。 我今天早上特别感激，截至周末，我们获得了一个新的创始成员。 请有一个幸福和希望的一周。